Co-Diagnostics, Inc. Common Stock (CODX)vsJohnson & Johnson (JNJ)
CODX
Co-Diagnostics, Inc. Common Stock
$1.53
-6.13%
HEALTHCARE · Cap: $5.94M
JNJ
Johnson & Johnson
$227.35
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 15479987% more annual revenue ($96.36B vs $622,490). JNJ leads profitability with a 21.8% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 59/100 (C).
CODX
Hold41
out of 100
Grade: D
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CODX.
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$227.35
$67.22 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 76.7% year-over-year
Earnings expanding 30.8% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -125.9% — below average capital efficiency
Negative free cash flow — burning cash
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : CODX
The strongest argument for CODX centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 76.7% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : CODX
The primary concerns for CODX are Market Cap, Profit Margin, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CODX profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
CODX carries more volatility with a beta of 1.43 — expect wider price swings.
CODX is growing revenue faster at 76.7% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 41/100), backed by strong 21.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Co-Diagnostics, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Co-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?